PPLPHARMA.NS Cash Flow
Piramal Pharma Ltd.
Profit & Loss Balance Sheet Cash Flow
Cash Flow · 4 years on file
(FY2022-23 to FY2025-26)
· fetched 2026-08-23 23:43
| Line item | FY2022-23 | FY2023-24 | FY2024-25 | FY2025-26 | Source (XBRL element) |
|---|---|---|---|---|---|
| Net Cash from Operating Activities | ₹4.84 Bn | ₹10.05 Bn | ₹8.92 Bn | ₹16.53 Bn | CashFlowsFromUsedInOperatingActivities |
| Net Cash from Investing Activities | ₹-13.39 Bn | ₹-4.34 Bn | ₹-4.77 Bn | ₹-8.26 Bn | CashFlowsFromUsedInInvestingActivities |
| Net Cash from Financing Activities | ₹8.18 Bn | ₹-4.22 Bn | ₹-4.41 Bn | ₹-0.39 Bn | CashFlowsFromUsedInFinancingActivities |
| Effect of Exchange Rate Changes | ₹0.05 Bn | ₹0.18 Bn | ₹-0.11 Bn | ₹0.06 Bn | EffectOfExchangeRateChangesOnCashAndCashEquivalents |
| Net Increase/(Decrease) in Cash | ₹-0.32 Bn | ₹1.66 Bn | ₹-0.37 Bn | ₹7.94 Bn | IncreaseDecreaseInCashAndCashEquivalents |
| Cash and Cash Equivalents (Closing) | ₹0.85 Bn | ₹0.53 Bn | N/A | N/A | CashAndCashEquivalentsCashFlowStatement |
Every figure above is the exact value of the named XBRL element from PPLPHARMA.NS's cached filing for that year — nothing here is estimated or backfilled. A company shows one column per year StockProof actually has data for — never padded with blank years. Rows shown as N/A are genuinely not disclosed under that year's filing format (see peer comparison for how other Healthcare companies compare).